Trial Profile

Phase 1 Clinical trial assessing safety and efficacy of paxalisib in combination with KEYTRUDA® (pembrolizumab) or LYNPARZA® (olaparib) in women with triple negative breast cancer.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paxalisib (Primary) ; Carboplatin; Gemcitabine; Olaparib; Paclitaxel; Pembrolizumab
Indications Advanced breast cancer; Triple negative breast cancer
Focus Adverse reactions
Acronyms ABC-Pax

09 Jan 2026 According to Kazia therapeutics media release, the company expects to provide a clinical and translational update before the end of the month from its ongoing Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer (TNBC).
10 Dec 2025 According to Kazia therapeutics media release, early clinical data from this 1st patient will be presented in a poster session at the 2025 San Antonio Breast Cancer Symposium (SABCS).
10 Dec 2025 Results presented in the Kazia therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com